Now showing items 1-8 of 8

    • Detection of circulating tumour cell clusters in human glioblastoma. 

      Krol, I; Castro-Giner, F; Maurer, M; Gkountela, S; Szczerba, BM; Scherrer, R; Coleman, N; Carreira, S; Bachmann, F; Anderson, S; Engelhardt, M; Lane, H; Evans, TRJ; Plummer, R; Kristeleit, R; Lopez, J; Aceto, N (2018-08)
      Human glioblastoma (GBM) is a highly aggressive, invasive and hypervascularised malignant brain cancer. Individual circulating tumour cells (CTCs) are sporadically found in GBM patients, yet it is unclear whether multicellular ...
    • Exploiting Synthetic Lethality and Network Biology to Overcome EGFR Inhibitor Resistance in Lung Cancer. 

      Vyse, S; Howitt, A; Huang, PH (2017-06)
      Despite the recent approval of third-generation therapies, overcoming resistance to epidermal growth factor receptor (EGFR) inhibitors remains a major challenge in non-small cell lung cancer. Conceptually, synthetic lethality ...
    • Genome-wide interaction and pathway-based identification of key regulators in multiple myeloma. 

      Chattopadhyay, S; Thomsen, H; Yadav, P; da Silva Filho, MI; Weinhold, N; Nöthen, MM; Hoffman, P; Bertsch, U; Huhn, S; Morgan, GJ; Goldschmidt, H; Houlston, R; Hemminki, K; Försti, A (2019-01)
      Inherited genetic susceptibility to multiple myeloma has been investigated in a number of studies. Although 23 individual risk loci have been identified, much of the genetic heritability remains unknown. Here we carried ...
    • Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. 

      Kar, SP; Beesley, J; Amin Al Olama, A; Michailidou, K; Tyrer, J; Kote-Jarai, Z; Lawrenson, K; Lindstrom, S; Ramus, SJ; Thompson, DJ; ABCTB Investigators; Kibel, AS; Dansonka-Mieszkowska, A; Michael, A; Dieffenbach, AK; Gentry-Maharaj, A; Whittemore, AS; Wolk, A; Monteiro, A; Peixoto, A; Kierzek, A; Cox, A; Rudolph, A; Gonzalez-Neira, A; Wu, AH; Lindblom, A; Swerdlow, A; AOCS Study Group & Australian Cancer Study (Ovarian Cancer); APCB BioResource; Ziogas, A; Ekici, AB; Burwinkel, B; Karlan, BY; Nordestgaard, BG; Blomqvist, C; Phelan, C; McLean, C; Pearce, CL; Vachon, C; Cybulski, C; Slavov, C; Stegmaier, C; Maier, C; Ambrosone, CB; Høgdall, CK; Teerlink, CC; Kang, D; Tessier, DC; Schaid, DJ; Stram, DO; Cramer, DW; Neal, DE; Eccles, D; Flesch-Janys, D; Edwards, DRV; Wokozorczyk, D; Levine, DA; Yannoukakos, D; Sawyer, EJ; Bandera, EV; Poole, EM; Goode, EL; Khusnutdinova, E; Høgdall, E; Song, F; Bruinsma, F; Heitz, F; Modugno, F; Hamdy, FC; Wiklund, F; Giles, GG; Olsson, H; Wildiers, H; Ulmer, H-U; Pandha, H; Risch, HA; Darabi, H; Salvesen, HB; Nevanlinna, H; Gronberg, H; Brenner, H; Brauch, H; Anton-Culver, H; Song, H; Lim, H-Y; McNeish, I; Campbell, I; Vergote, I; Gronwald, J; Lubiński, J; Stanford, JL; Benítez, J; Doherty, JA; Permuth, JB; Chang-Claude, J; Donovan, JL; Dennis, J; Schildkraut, JM; Schleutker, J; Hopper, JL; Kupryjanczyk, J; Park, JY; Figueroa, J; Clements, JA; Knight, JA; Peto, J; Cunningham, JM; Pow-Sang, J; Batra, J; Czene, K; Lu, KH; Herkommer, K; Khaw, K-T; kConFab Investigators; Matsuo, K; Muir, K; Offitt, K; Chen, K; Moysich, KB; Aittomäki, K; Odunsi, K; Kiemeney, LA; Massuger, LFAG; Fitzgerald, LM; Cook, LS; Cannon-Albright, L; Hooning, MJ; Pike, MC; Bolla, MK; Luedeke, M; Teixeira, MR; Goodman, MT; Schmidt, MK; Riggan, M; Aly, M; Rossing, MA; Beckmann, MW; Moisse, M; Sanderson, M; Southey, MC; Jones, M; Lush, M; Hildebrandt, MAT; Hou, M-F; Schoemaker, MJ; Garcia-Closas, M; Bogdanova, N; Rahman, N; NBCS Investigators; Le, ND; Orr, N; Wentzensen, N; Pashayan, N; Peterlongo, P; Guénel, P; Brennan, P; Paulo, P; Webb, PM; Broberg, P; Fasching, PA; Devilee, P; Wang, Q; Cai, Q; Li, Q; Kaneva, R; Butzow, R; Kopperud, RK; Schmutzler, RK; Stephenson, RA; MacInnis, RJ; Hoover, RN; Winqvist, R; Ness, R; Milne, RL; Travis, RC; Benlloch, S; Olson, SH; McDonnell, SK; Tworoger, SS; Maia, S; Berndt, S; Lee, SC; Teo, S-H; Thibodeau, SN; Bojesen, SE; Gapstur, SM; Kjær, SK; Pejovic, T; Tammela, TLJ; GENICA Network; PRACTICAL consortium; Dörk, T; Brüning, T; Wahlfors, T; Key, TJ; Edwards, TL; Menon, U; Hamann, U; Mitev, V; Kosma, V-M; Setiawan, VW; Kristensen, V; Arndt, V; Vogel, W; Zheng, W; Sieh, W; Blot, WJ; Kluzniak, W; Shu, X-O; Gao, Y-T; Schumacher, F; Freedman, ML; Berchuck, A; Dunning, AM; Simard, J; Haiman, CA; Spurdle, A; Sellers, TA; Hunter, DJ; Henderson, BE; Kraft, P; Chanock, SJ; Couch, FJ; Hall, P; Gayther, SA; Easton, DF; Chenevix-Trench, G; Eeles, R; Pharoah, PDP; Lambrechts, D (2016-09)
      UNLABELLED:Breast, ovarian, and prostate cancers are hormone-related and may have a shared genetic basis, but this has not been investigated systematically by genome-wide association (GWA) studies. Meta-analyses combining ...
    • The genomic landscape of testicular germ cell tumours: from susceptibility to treatment. 

      Litchfield, K; Levy, M; Huddart, RA; Shipley, J; Turnbull, C (2016-07)
      The genomic landscape of testicular germ cell tumour (TGCT) can be summarized using four overarching hypotheses. Firstly, TGCT risk is dominated by inherited genetic factors, which determine nearly half of all disease risk ...
    • MicroRNA and gene co-expression networks characterize biological and clinical behavior of rhabdomyosarcomas. 

      Missiaglia, E; Shepherd, CJ; Aladowicz, E; Olmos, D; Selfe, J; Pierron, G; Delattre, O; Walters, Z; Shipley, J (2017-01)
      Rhabdomyosarcomas (RMS) in children and adolescents are heterogeneous sarcomas broadly defined by skeletal muscle features and the presence/absence of PAX3/7-FOXO1 fusion genes. MicroRNAs are small non-coding RNAs that ...
    • SiGNet: A signaling network data simulator to enable signaling network inference. 

      Coker, EA; Mitsopoulos, C; Workman, P; Al-Lazikani, B (2017-01)
      Network models are widely used to describe complex signaling systems. Cellular wiring varies in different cellular contexts and numerous inference techniques have been developed to infer the structure of a network from ...
    • Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer. 

      Wagner, S; Vlachogiannis, G; De Haven Brandon, A; Valenti, M; Box, G; Jenkins, L; Mancusi, C; Self, A; Manodoro, F; Assiotis, I; Robinson, P; Chauhan, R; Rust, AG; Matthews, N; Eason, K; Khan, K; Starling, N; Cunningham, D; Sadanandam, A; Isacke, CM; Kirkin, V; Valeri, N; Whittaker, SR (2019-03)
      Despite showing clinical activity in BRAF-mutant melanoma, the MEK inhibitor (MEKi) trametinib has failed to show clinical benefit in KRAS-mutant colorectal cancer. To identify mechanisms of resistance to MEKi, we employed ...